Hemogenyx Pharmaceuticals plc (LSE:HEMO) reported a wider first-half loss of £6.56m, mostly reflecting a non-cash share-based payment charge, while its lead CAR-T therapy HG-CT-1 was cleared for dose escalation in adults and to open a paediatric arm.

What was announced

Hemogenyx (LSE:HEMO), a biopharmaceutical company developing treatments for blood diseases whose shares are listed in the transition category of the Official List, published unaudited half-year results for the six months to 30 June 2026 on 28 September 2026.

The company's lead product is HG-CT-1, a CAR-T cell therapy targeting FLT3 for relapsed or refractory acute myeloid leukaemia (AML). In its second annual IND report, submitted to the US Food and Drug Administration in April 2026, Hemogenyx reported that three adult patients treated at the lowest dose level showed CAR-T cell expansion and persistence, peaking 14 to 28 days after infusion, along with reductions in blast burden in blood or bone marrow. No neurotoxicity (ICANS) or dose-limiting toxicities were observed, and adverse events were described as low-grade and manageable.

A data safety monitoring board had advised dose escalation in October 2025, and the trial is now cleared to escalate in adults. The FDA has also cleared a paediatric arm, and the company said a first paediatric patient was identified after the period end.

The numbers

Loss before tax rose to £6,557,736 from £5,006,415 in the first half of 2025. Operating costs were £6,481,401 (£4,886,532), including a non-cash share-based payment charge of £5,543,473. The company said that, excluding this charge, operating costs were lower than a year earlier. During the period it granted 1,260,000 Options at £8.00 and 333,333 warrants at £9.00.

Cash at 30 June 2026 was £4,584,849, up from £1,586,430 at 31 December 2025. Hemogenyx raised £5.6m in the half, including £3.0m from institutional investors, issuing 707,865 shares through placings and 50,841 through Warrant exercises. After the period end, warrant exercise notices for 96,825 shares raised a further £291,665.

The loss per share is shown as 1.017 on a weighted average of 6,444,216 shares. By calculation, the loss divided by that share count is about £1.02 per share, so the figure appears to be in pounds rather than pence; the unit was not confirmed in the announcement.

The directors reported a material uncertainty over going concern. Their 12-month Cash Flow forecasts show that additional Capital is needed for planned HG-CT-1 development, and no funding was committed at the approval date, although the board expressed confidence in raising it.

Manufacturing and partnerships

Technology transfer to contract manufacturer Made Scientific has been completed, and a comparability data package has been submitted to the FDA. On 11 August 2026 Hemogenyx signed a definitive agreement with Cellin Technologies OÜ in Estonia, giving Cellin a five-year exclusive role in Manufacturing and clinical implementation under Estonia's hospital exemption pathway. Technology transfer is expected to take about four months and regulatory review about 90 days. Net operating margins will be shared, and Hemogenyx retains intellectual property and rights outside Estonia. The company cautions that hospital exemption is not a full Marketing authorisation and that no minimum revenues are assured.

On 29 July 2026 it signed a non-binding letter of intent with Vilnius University Hospital Santaros Klinikos in Lithuania covering clinical development and point-of-care manufacturing.

Chairman Marc Feldmann said the half "delivered what it needed to deliver: a trial cleared to escalate in adults and to open in children, a manufacturing base capable of supporting it, the first binding commercial arrangement for the therapy, and the capital [to] advance the programme."

What to watch next

The company's stated priorities are adult dose escalation, paediatric enrolment, the Estonian technology transfer and hospital exemption submission, and progress on the Lithuanian collaboration. Development of its CDX bi-specific antibody and Chimeric Bait Receptor platform continues.